Paredes Nethnapha, Wang Aimin, Berry Leslie R, Smith Lesley J, Stafford Alan R, Weitz Jeffrey I, Chan Anthony K C
Henderson Research Centre, Hamilton, Ontario L8V 1C3.
J Biol Chem. 2003 Jun 27;278(26):23398-409. doi: 10.1074/jbc.M302895200. Epub 2003 Apr 14.
Covalent antithrombin-heparin (ATH) complexes, formed spontaneously between antithrombin (AT) and unfractionated standard heparin (H), have a potent ability to catalyze the inhibition of factor Xa (or thrombin) by added AT. Although approximately 30% of ATH molecules contain two AT-binding sites on their heparin chains, the secondary site does not solely account for the increased activity of ATH. We studied the possibility that all pentasaccharide AT-binding sequences in ATH may catalyze factor Xa inhibition. Chromatography of ATH on Sepharose-AT resulted in >80% binding of the load. Similar chromatographies of non-covalent AT + H mixtures lead to a lack of binding for AT and fractionation of H into unbound (separate from AT) or bound material. Gradient elution of ATH from Sepharose-AT gave 2 peaks, a peak containing higher affinity material that had greater anti-factor Xa catalytic activity (708 units/mg heparin) compared with the peak containing lower affinity material (112 units/mg). Sepharose-AT chromatography of the ATH component with short heparin chains (<or=12 monosaccharides) resulted in active unbound (40%) and bound fractions (190 and 560 units/mg, respectively). Factor Xa-ATH or thrombin-ATH inhibitor complexes gave chromatograms on Sepharose-AT with more unbound material compared with that of free ATH. Also, ATH did not bind to Sepharose-heparin, and the intrinsic fluorescence due to activation of AT in ATH by its heparin chain was reversed at higher [NaCl] than that required to dissociate non-covalent AT.H complexes. Thus, exogenous AT can compete with the AT moiety of ATH for binding to the covalently linked heparin chain, leading to catalytic inhibition of factor Xa or thrombin. These data may suggest that access to pentasaccharide units in non-covalent AT.H complexes by free AT may be facile.
抗凝血酶与肝素(ATH)的共价复合物是在抗凝血酶(AT)和未分级的标准肝素(H)之间自发形成的,具有强大的能力来催化添加的AT对因子Xa(或凝血酶)的抑制作用。尽管大约30%的ATH分子在其肝素链上含有两个AT结合位点,但次要位点并不能单独解释ATH活性的增加。我们研究了ATH中所有五糖AT结合序列可能催化因子Xa抑制的可能性。ATH在琼脂糖-AT上的色谱分析导致负载物的结合率>80%。非共价AT+H混合物的类似色谱分析导致AT缺乏结合,并且H被分离为未结合(与AT分离)或结合物质。从琼脂糖-AT上对ATH进行梯度洗脱得到2个峰,一个峰含有较高亲和力的物质,其抗因子Xa催化活性(708单位/毫克肝素)高于含有较低亲和力物质的峰(112单位/毫克)。对具有短肝素链(≤12个单糖)的ATH组分进行琼脂糖-AT色谱分析,得到活性未结合部分(40%)和结合部分(分别为190和560单位/毫克)。与游离ATH相比,因子Xa-ATH或凝血酶-ATH抑制剂复合物在琼脂糖-AT上的色谱图中有更多的未结合物质。此外,ATH不与琼脂糖-肝素结合,并且由于其肝素链激活ATH中的AT而产生的固有荧光在高于解离非共价AT.H复合物所需的[NaCl]浓度下被逆转。因此,外源性AT可以与ATH的AT部分竞争与共价连接的肝素链的结合,导致对因子Xa或凝血酶的催化抑制。这些数据可能表明游离AT能够轻易接近非共价AT.H复合物中的五糖单元。